Book Reviews

Congress and the Court By Walter F. Murphy. Chicago: The University of Chicago Press, 1962. Pp. xi, 308. $6.95. (judicial power) reviewer: Senator Estes Kefauver =============================== Interstate Apportionment of Business Income for State Income Tax Purposes By Charles E. Ratliff, Jr. Chapel Hill: The University of North Carolina Press, 1962. Pp. xi, 132.$4.00. (tax law) reviewer: Stanley D. Rose ================================= Expulsion or Oppression of Business Associates By F. Hodge O\u27Neal and Jordan Derwin. Durham, N.C.: Duke University Press,1961. Pp. vii, 263. $10.00. (business organizations) reviewer: W. EDWARD SELL ================================= The Ideologies of Taxation By Louis Eisenstein. New York: The Ronald Press Company: 1961. Pp. vii, 263.$5.00. (tax law) reviewer: Harold G. Wren =============================== Corporate Liquidations for the Lawyer and the Accountant By Howard A. Rumpf. Englewood Cliffs, N.J.: Prentice Hall, Inc.:1962. Pp. 238. $17.50. (corporate law) reviewer: Harold C. Wren ================================ Essays in Jurisprudence in Honor of Roscoe Pound Edited by Ralph A. Newman. Indianapolis: Bobbs-Merrill Co., 1962. Pp.xxiii, 670.$12.00. (jurisprudence) reviewer: Robert N. Covingto

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m2 i.v. over 1 h on days 1 to 10. Fifty-three subjects enrolled with a median age of 74 years (range, 60–85). Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had complex karyotypes (≥3 abnormalities). The complete remission rate was 47% (n = 25), achieved after a median of three cycles of therapy. Nine additional subjects had no morphologic evidence of disease with incomplete count recovery, for an overall response rate of 64% (n = 34). Complete remission was achieved in 52% of subjects presenting with normal karyotype and in 50% of those with complex karyotypes. Median overall and disease-free survival durations were 55 and 46 weeks, respectively. Death within 30 days of initiation of treatment occurred in one subject (2%), death within 8 weeks in 15% of subjects. Given the DNA hypomethylating effect of decitabine, we examined the relationship of clinical response and pretreatment level of miR-29b, previously shown to target DNA methyltransferases. Higher levels of miR-29b were associated with clinical response (P = 0.02). In conclusion, this schedule of decitabine was highly active and well tolerated in this poor-risk cohort of older AML patients. Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment